Literature DB >> 9185025

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

P Marques-Vidal1, J Tuomilehto.   

Abstract

One of the cornerstones of the primary prevention of cardiovascular disease has been screening and early antihypertensive drug treatment of patients with high blood pressure (BP). Nevertheless, recent population studies have shown that awareness and management of high BP levels are far from optimal. In this study, we performed a search for publications providing frequencies of hypertension awareness, treatment and control in different populations. In men, the frequencies of awareness, antihypertensive drug treatment and BP control among all hypertensive patients varied between 23% and 93%, 5% and 89% and 5% and 87%, respectively. In women, the frequencies ranged between 28% and 97%, 6% and 97%, and 0% and 97%, respectively. The percentage of aware hypertensives who were under antihypertensive drug treatment varied between 47% and 95% in men and between 50% and 100% in women. The percentage of hypertensives who were under antihypertensive drug treatment varied between 47% and 95% in men and between 50% and 100% in women. The percentage of treated hypertensives achieving an adequate BP control varied between 29% and 95% in men and between 0% and 100% in women. Overall, women had a better awareness, treatment and control status for hypertension than men, and worse in developing countries than in industrialised countries. Hypertension awareness, treatment and control improved with time, together with the proportion of diagnosed hypertensive patients under treatment and the proportion of well controlled among treated hypertensive patients. We conclude that although the 'rule of halves' no longer applies for screening and treatment of hypertension in industrialised countries, it might still be valid for developing countries and for the effectiveness of antihypertensive drug treatment in all countries.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185025     DOI: 10.1038/sj.jhh.1000426

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  44 in total

1.  New Canadian hypertension recommendations. So what?

Authors:  N R Campbell
Journal:  Can Fam Physician       Date:  2000-07       Impact factor: 3.275

Review 2.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

3.  Influence of education and working background on physicians' knowledge of secondary prevention guidelines for coronary heart disease: results from a survey in China.

Authors:  Yan-Jun Gong; Tao Hong; Jie Jiang; Rong-Hui Yu; Yan Zhang; Zhao-Ping Liu; Yong Huo
Journal:  J Zhejiang Univ Sci B       Date:  2012-03       Impact factor: 3.066

4.  Prevalence, awareness, treatment, and control of hypertension: rule of thirds in the Skaraborg project.

Authors:  Ulf Lindblad; Johanna Ek; Jenny Eckner; Charlotte A Larsson; Guangliang Shan; Lennart Råstam
Journal:  Scand J Prim Health Care       Date:  2012-06       Impact factor: 2.581

5.  High prevalence, low awareness, treatment and control rates of hypertension in Guinea: results from a population-based STEPS survey.

Authors:  A Camara; N M Baldé; M Diakité; D Sylla; E H Baldé; A P Kengne; M D Baldé
Journal:  J Hum Hypertens       Date:  2015-08-27       Impact factor: 3.012

6.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

7.  Impact of the pay-for-performance contract and the management of hypertension in Scottish primary care: a 6-year population-based repeated cross-sectional study.

Authors:  Colin R Simpson; Philip C Hannaford; Lewis D Ritchie; Aziz Sheikh; David Williams
Journal:  Br J Gen Pract       Date:  2011-07       Impact factor: 5.386

Review 8.  Clinical implications of indapamide sustained release 1.5 mg in hypertension.

Authors:  R Donnelly
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 9.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention.

Authors:  Miia Kivipelto; Mikko P Laakso; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.